Resected stage III cutaneous melanoma — adjuvant-eligible biology (positive sentinel-lymp...
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | RF-MELANOMA-STAGE-III-RESECTED |
|---|---|
| Тип | Тривожна ознака |
| Статус | переглянуто 2026-04-30 | очікує клінічного підпису |
| Хвороби | DIS-MELANOMA |
| Джерела | SRC-CHECKMATE-238-WEBER-2017 SRC-COMBI-AD-LONG-2017 SRC-ESMO-MELANOMA-2024 SRC-KEYNOTE-054-EGGERMONT-2018 SRC-NCCN-MELANOMA-2025 |
Походження тривожної ознаки
| Визначення | Resected stage III cutaneous melanoma — adjuvant-eligible biology (positive sentinel-lymph-node biopsy or clinically detected nodal disease, surgically resected via wide local excision ± completion lymphadenectomy or therapeutic neck/inguinal dissection per surgical judgment). Treatment-defining: shifts the patient out of the metastatic 1L pathway into adjuvant immunotherapy (KEYNOTE-054 pembrolizumab × 12 months, CheckMate-238 nivolumab × 12 months) or adjuvant BRAFi+MEKi (COMBI-AD dabrafenib + trametinib) for BRAF V600 mutants. Adjuvant therapy initiated within 12 weeks of definitive surgery per the registration trials. |
|---|---|
| Клінічний напрям | intensify |
| Категорія | high-risk-biology |
| Змінює алгоритм | ALGO-MELANOMA-METASTATIC-1L, ALGO-MELANOMA-ADJUVANT-1L |
Логіка спрацьовування
{
"all_of": [
{
"finding": "stage_iii",
"value": true
},
{
"finding": "stage_iv",
"value": false
},
{
"any_of": [
{
"finding": "resection_status",
"value": "R0_resected"
},
{
"finding": "resection_status",
"value": "R1_resected"
},
{
"finding": "wide_local_excision_completed",
"value": true
}
]
}
],
"type": "stage_resection_composite"
}
Нотатки
Engine wiring: when resected-stage-III biology is detected on a patient profile that lacks `disease_state` (so the metastatic-1L algorithm is the only line=1 algorithm available by load-order fallback), this RedFlag fires inside ALGO-MELANOMA-METASTATIC-1L step 0 to redirect the engine to the adjuvant indication (IND-MELANOMA-ADJUVANT-PEMBRO-STAGE-III) instead of the metastatic-1L default. Once curated patient JSONs migrate to set `disease_state: "adjuvant"`, ALGO-MELANOMA-ADJUVANT-1L picks them up directly and this step 0 becomes redundant (still safe — it's additive). KEYNOTE-054 BRAF-WT and BRAF-mut both eligible — adjuvant pembro is the standard-track default; aggressive-track substitution to dabra+trame (COMBI-AD) is BRAF-mut subgroup only.
Де використовується
Algorithms
ALGO-MELANOMA-ADJUVANT-1L- ALGO-MELANOMA-ADJUVANT-1LALGO-MELANOMA-METASTATIC-1L- ALGO-MELANOMA-METASTATIC-1L